Brokers Offer Predictions for ACRS FY2025 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a research note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal anticipates that the biotechnology company will post earnings per share of ($0.54) for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Aclaris Therapeutics' current full-year earnings is ($0.82) per share.

ACRS has been the subject of a number of other research reports. Leerink Partners upgraded Aclaris Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price objective for the company from $2.00 to $7.00 in a research note on Tuesday, November 19th. Scotiabank began coverage on shares of Aclaris Therapeutics in a research report on Friday. They set a "sector outperform" rating and a $15.00 price target for the company. HC Wainwright upgraded Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $20.00 price target on the stock in a report on Monday, December 23rd. Leerink Partnrs raised Aclaris Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, November 19th. Finally, StockNews.com lowered Aclaris Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, February 8th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $11.67.

Remove Ads

Aclaris Therapeutics Price Performance

Shares of ACRS traded down $0.17 during midday trading on Thursday, reaching $1.66. The stock had a trading volume of 912,724 shares, compared to its average volume of 1,144,626. Aclaris Therapeutics has a 1-year low of $0.95 and a 1-year high of $5.17. The company has a market cap of $179.15 million, a price-to-earnings ratio of -3.19 and a beta of 0.48. The company's fifty day simple moving average is $2.34 and its two-hundred day simple moving average is $2.19.

Hedge Funds Weigh In On Aclaris Therapeutics

A number of large investors have recently bought and sold shares of the stock. Assenagon Asset Management S.A. grew its stake in Aclaris Therapeutics by 113.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 397,362 shares of the biotechnology company's stock worth $985,000 after buying an additional 211,585 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Aclaris Therapeutics by 187.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company's stock worth $382,000 after purchasing an additional 216,826 shares during the last quarter. BML Capital Management LLC increased its stake in Aclaris Therapeutics by 9.7% during the third quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company's stock valued at $16,388,000 after purchasing an additional 1,261,866 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Aclaris Therapeutics by 9.3% in the 3rd quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company's stock worth $974,000 after acquiring an additional 72,309 shares during the period. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Aclaris Therapeutics in the 3rd quarter worth $1,053,000. Hedge funds and other institutional investors own 98.34% of the company's stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.